AR047782A1 - SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE - Google Patents

SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE

Info

Publication number
AR047782A1
AR047782A1 ARP040104928A AR047782A1 AR 047782 A1 AR047782 A1 AR 047782A1 AR P040104928 A ARP040104928 A AR P040104928A AR 047782 A1 AR047782 A1 AR 047782A1
Authority
AR
Argentina
Prior art keywords
drospirenone
speed
combination
pharmaceutical composition
ethylynestradiol
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Daniel Zanetti
Gustavo Andrade
Original Assignee
Gador Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gador Sa filed Critical Gador Sa
Priority to ARP040104928 priority Critical patent/AR047782A1/en
Priority to UY29227A priority patent/UY29227A1/en
Priority to CO05130115A priority patent/CO5770093A1/en
Priority to PE2006000018A priority patent/PE20061112A1/en
Publication of AR047782A1 publication Critical patent/AR047782A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se relaciona con una composicion farmacéutica asegurando una velocidad de disolucion y homogenizacion de la droga no micronizada logrando una estabilidad físico-química inesperada. También con la composicion farmacéutica obtenida por ese proceso y el uso de la composicion farmacéutica para preparar un medicamento. La composicion farmacéutica comprende, una combinacion de dos principios activos, a saber drospirenona y etinilestradiol, un agente surfactante y excipientes farmacéuticamente aceptables con la condicion de que la drospirenona presente la siguiente distribucion: aproximadamente el 95 % de ellos presenten un tamano de partícula inferior a 100 (mu)m, aproximadamente el 26 % presente un tamano de partícula inferior a 20 (mu)m y aproximadamente el 15 % presente un tamano de partícula inferior a 1.000 (mu)m, o con la condicion de que dichos principios activos presenten un área superficial menor a 10.000 cm2/g o con la condicion que la drospirenona no se encuentra en forma micronizada. Esta composicion es usada para inhibir la ovulacion y los cambios en la secrecion cervical.This is related to a pharmaceutical composition ensuring a speed of dissolution and homogenization of the non-micronized drug achieving unexpected physical-chemical stability. Also with the pharmaceutical composition obtained by that process and the use of the pharmaceutical composition to prepare a medicine. The pharmaceutical composition comprises, a combination of two active ingredients, namely drospirenone and ethinyl estradiol, a pharmaceutically acceptable surfactant and excipients with the proviso that drospirenone has the following distribution: approximately 95% of them have a particle size less than 100 (mu) m, approximately 26% have a particle size of less than 20 (mu) m and approximately 15% have a particle size of less than 1,000 (mu) m, or with the proviso that said active ingredients have a surface area less than 10,000 cm2 / g or with the condition that drospirenone is not in micronized form. This composition is used to inhibit ovulation and changes in cervical secretion.

ARP040104928 2004-12-28 2004-12-28 SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE AR047782A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ARP040104928 AR047782A1 (en) 2004-12-28 2004-12-28 SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE
UY29227A UY29227A1 (en) 2004-12-28 2005-11-24 SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYNYLESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENT A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLUTION INSURED FOR NON-MICRONIZED DRUG
CO05130115A CO5770093A1 (en) 2004-12-28 2005-12-27 SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLINESTRADIOL AND AN APPROPRIATE SOUTHFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, RPOCEDI
PE2006000018A PE20061112A1 (en) 2004-12-28 2006-01-03 PHARMACEUTICAL COMPOSITIONS INCLUDING DROSPIRENONE, ETHINYLESTRADIOL AND SURFACTING AGENT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040104928 AR047782A1 (en) 2004-12-28 2004-12-28 SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE

Publications (1)

Publication Number Publication Date
AR047782A1 true AR047782A1 (en) 2006-02-22

Family

ID=36607162

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104928 AR047782A1 (en) 2004-12-28 2004-12-28 SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE

Country Status (4)

Country Link
AR (1) AR047782A1 (en)
CO (1) CO5770093A1 (en)
PE (1) PE20061112A1 (en)
UY (1) UY29227A1 (en)

Also Published As

Publication number Publication date
CO5770093A1 (en) 2007-06-29
PE20061112A1 (en) 2006-11-27
UY29227A1 (en) 2005-12-30

Similar Documents

Publication Publication Date Title
JP6082249B2 (en) Transdermal gel preparation
Moghissi Medical treatment of endometriosis
US8647665B2 (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application
US20110245215A1 (en) Transdermal delivery systems for active agents
ES2281551T3 (en) METHOD OF PREVENTION OR TREATMENT OF BENIGN GYNECOLOGICAL DISEASES.
EP2246049A3 (en) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs
AR018410A1 (en) USE OF A COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT USED FOR THE PREVENTION OR TREATMENT OF AN ACUTE STATE OF ASTHMA AND / OR ASTHMA INTERMITENTEY / OR EPISODES OF CHRONIC ASTHMA AND METHOD FOR THE PREVENTION OR TREATMENT OF AN ACUTE STATE OF ASTHMA AND / OR INTERMITTENT ASTHMA AND / OR ASTHON CRON EPISODES
KR20060054320A (en) Transdermal hormone delivery system: compositions and methods
MEP38008A (en) Drospirenone for hormone replacement therapy
JP2009519958A (en) Fluxable compositions and methods for skin delivery of drugs
CN106604717B (en) Topical diclofenac sodium compositions
TW200514560A (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
KR970706001A (en) PROCESS OF MAKING DOSAGE UNITS BY WET GRANULATION BY WET-GRANULATION
Pearson et al. Antiestrogen treatment of breast cancer: an overview
WO2000007599A1 (en) Prevention of endometriosis signs or symptoms
AR045719A1 (en) PHARMACEUTICAL FORMULATION THAT INCLUDES SODIUM LEVOTIROXIN, MICROCRYSTALLINE CELLULOSE AND PREGELATINIZED ALMIDON; USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCESS TO PREPARE THIS FORMULATION
AR036970A1 (en) ANDROGENIC PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DEPRESSION
AR047782A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE
AR045576A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DROSPIRENONE AND ETHYLESTRADIOL
DOP2005000278A (en) SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENON, ETHYLINESTRADIOL AND A SUITABLE SURFACTANT AGENT THAT PRESENT A HOMOGENEITY OF CONTAINED SPEED AND SPEED OF DRUG FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION FOR COMPOSITION PREPARATION.
Von Schoultz Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment
RU2000115313A (en) GESTAGEN-ANTI-GESTAGEN RECEPTION DIAGRAMS
PE20010665A1 (en) A PHARMACEUTICAL COMPOSITION OF DROSPIRENONE AND ETHINYLESTRADIOL TO BE USED AS A CONTRACEPTIVE
Sitruk-Ware et al. Patent: Nestorone®/estradiol transdermal gel
AR026747A1 (en) EPERENONA CRYSTAL FORM

Legal Events

Date Code Title Description
FB Suspension of granting procedure